These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 10636336)

  • 1. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling.
    Machado SG; Miller R; Hu C
    Stat Methods Med Res; 1999 Sep; 8(3):217-45. PubMed ID: 10636336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic data and models in clinical trials.
    Steimer JL; Ebelin ME; Van Bree J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):61-76. PubMed ID: 8335040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.
    Van Peer A; Snoeck E; Huang ML; Heykants J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):49-59. PubMed ID: 8335039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical cross-over trials in phase I.
    Senn S; Ezzet F
    Stat Methods Med Res; 1999 Sep; 8(3):263-78. PubMed ID: 10636338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
    Csajka C; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
    Lees P; Giraudel J; Landoni MF; Toutain PL
    J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
    Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
    Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic modelling in drug development.
    Aarons L
    Stat Methods Med Res; 1999 Sep; 8(3):181-2. PubMed ID: 10636333
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling.
    Höcht C; Opezzo JA; Bramuglia GF; Taira CA
    Expert Opin Drug Discov; 2006 Sep; 1(4):289-301. PubMed ID: 23495900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population modelling in drug development.
    Sheiner L; Wakefield J
    Stat Methods Med Res; 1999 Sep; 8(3):183-93. PubMed ID: 10636334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
    Toutain PL; Lees P
    J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.